Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data

AdComrejectedNegative

AI Analysis

Summary

Capricor Therapeutics received a negative FDA advisory committee vote on its Duchenne muscular dystrophy therapy and plans to submit additional data and analyses to the FDA for reconsideration of approval in a narrower patient population.

Outcome Details

Negative FDA advisory committee vote

Importance:7/10

Sentiment:

-0.60

DMDregulatory setbackFDA reviewadvisory committee

Related Companies

$BTTX

Read the original article

Published by Endpoints News on August 14, 2026 3:33 PM

Read Original